DWP 10292

Drug Profile

DWP 10292

Alternative Names: DWP10292

Latest Information Update: 14 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic fatty liver disease
  • Discontinued Retinitis pigmentosa

Most Recent Events

  • 01 Feb 2016 Daewoong Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (PO) (NCT02622685)
  • 01 May 2015 Daewoong Pharmaceutical initiates a phase I trial in Healthy volunteers in South Korea (PO) (NCT02622685)
  • 10 Oct 2012 Phase-I development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top